title: [Clinical trials of oral recombinant bivaccine against variola and hepatitis B during double vaccination].
abstract: Clinical trials of oral live recombinant embryonic variola and hepatitis B bivaccine as tablets (Revax-BT) were performed. When volunteers were prevaccinated with oral variola vaccine first in a small dose and, 7, 14, 30, 90, and 180 days later, in a larger dose, a slight reactoginicity was sometimes observed after the first vaccination (with a small dose) whereas revaccination with a larger dose did not give rise to any clinical manifestations. A month after vaccination, a protective level of virus-neutralizing antibodies to vaccinia virus (VV) was observed in 90-100% of the volunteers twice immunized with the bivaccine (in a small dose and in a larger one at an administration intervals of 1-2 weeks under remote revaccination while 6-9 months following vaccination, this level was recorded in 80% of the volunteers. A month following vaccination, 50-55% seroconversion to VV was observed in the volunteers twice immunized with the bivaccine (at an interval of 1 or 3-6 months). Cellular immunity to VV was low (0-20%). Double immunization of volunteers with the oral bivaccine under remote vaccination failed to produce the significant levels of humoral and cellular immune responses to hepatitis B markers. Recombinant VV was not recorded in any blood, saliva, and urine samples taken in the volunteers twice immunized with the bivaccine.
authors.forename: I V
authors.initials: IV
authors.lastname: Pliasunov
authors.forename: A N
authors.initials: AN
authors.lastname: Sergeev
authors.forename: A A
authors.initials: AA
authors.lastname: Sergeev
authors.forename: V A
authors.initials: VA
authors.lastname: Petrishchenko
authors.forename: L N
authors.initials: LN
authors.lastname: Shishkina
authors.forename: V V
authors.initials: VV
authors.lastname: Generalov
authors.forename: A S
authors.initials: AS
authors.lastname: Safatov
authors.forename: L S
authors.initials: LS
authors.lastname: Sandakhchiev
authors.forename: V V
authors.initials: VV
authors.lastname: Udut
authors.forename: S A
authors.initials: SA
authors.lastname: Mel'nikov
authors.forename: V N
authors.initials: VN
authors.lastname: Podkuĭko
mesh_terms: D000284:Administration, Oral; D000914:Antibodies, Viral / Q000097:blood*; D019433:Chickenpox Vaccine / Q000008:administration & dosage / Q000276:immunology*; D004334:Drug Administration Schedule; D006509:Hepatitis B / Q000276:immunology*; D006510:Hepatitis B Antibodies / Q000097:blood; D017325:Hepatitis B Vaccines / Q000008:administration & dosage / Q000276:immunology*; D006801:Humans; D007111:Immunity, Cellular; D009500:Neutralization Tests; D012899:Smallpox / Q000276:immunology*; D013607:Tablets / Q000008:administration & dosage; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000032:analysis / Q000276:immunology
chemical_list: D000914:Antibodies, Viral; D019433:Chickenpox Vaccine; D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines; D013607:Tablets; D014614:Vaccines, Synthetic